Retifanlimab-dlwr (Zynyz) was granted approval from the FDA for treatment of locally recurrent or metastatic squamous cell ...

A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, ...

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to ...

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a ...

Panelists discuss how real-world data from the San Antonio Breast Cancer Symposium demonstrated that elacestrant's ...

Patients with stage III and high-risk stage II colon cancer who participated in an exercise program saw improved disease-free ...

Patients with HR-positive, HER2-negative metastatic breast cancer should be consistently tested for ESR1 mutations to inform ...

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients ...

The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.

The FDA has approved the VENTANA MET (SP44) RxDx Assay as a companion diagnostic to identify individuals with non–small cell ...

The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.

Adding immunotherapy to chemo may boost pCR and downstaging rates in the neoadjuvant setting for muscle-invasive bladder ...